Other observed topics

immune checkpoint inhibitors

Observed in 142 articles across 16 journals.

Steady

Latest share0.17%

Change vs baseline-0.08 pp

Months observed13

Latest monthJul 2026

Portfolio article share

Attention over this snapshot

13 monthly points

Journal breadth

Where it appears

Journal for ImmunoTherapy of Cancer102
European Journal of Hospital Pharmacy6
Gut6
Journal of Neurology, Neurosurgery & Psychiatry5
BMJ Case Reports4
BMJ Open4
BMJ Oncology3
Thorax3
Heart2
BMJ Immunology1
Frontline Gastroenterology1
Journal of Clinical Pathology1

Co-occurrence

Explore nearby topics

Inspect the source signal

Article evidence

30 high-ranking examples

Journal for ImmunoTherapy of Cancer · 2026-06-24

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study

Phrase rank #1 · DOI 10.1136/jitc-2025-013748

Journal of Scleroderma and Related Disorders · 2026-06-05

P.194 Raynaud’s phenomenon in the setting of immune checkpoint inhibitors: a case series and possible implications

Phrase rank #1 · DOI 10.1136/JSRD-2026-SSWC.238

Journal for ImmunoTherapy of Cancer · 2026-04-21

Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma

Phrase rank #1 · DOI 10.1136/jitc-2025-014070

Thorax · 2026-04-17

Sex-based differences in effectiveness of immune checkpoint inhibitors in the treatment of advanced non-small-cell lung cancer: systematic review and meta-analysis

Phrase rank #1 · DOI 10.1136/thorax-2025-223372

European Journal of Hospital Pharmacy · 2026-03-18

5PSQ-093 Myocarditis-myositis-myasthenia gravis overlap syndrome: an emerging severe adverse reaction among immune checkpoint inhibitors. Analysis of reports in the Spanish adverse reactions database (FEDRA)

Phrase rank #1 · DOI 10.1136/ejhpharm-2026-eahp.519

European Journal of Hospital Pharmacy · 2026-03-18

5PSQ-089 Impact of proton pump inhibitor exposure on progression-free and overall survival in patients treated with immune checkpoint inhibitors

Phrase rank #1 · DOI 10.1136/ejhpharm-2026-eahp.515

BMJ Open · 2025-12-30

Efficacy and safety of adjuvant short-course immune checkpoint inhibitors following TACE combined with MWA in patients with BCLC A–B hepatocellular carcinoma: a single-arm, prospective, phase II study protocol

Phrase rank #1 · DOI 10.1136/bmjopen-2025-111786

Journal for ImmunoTherapy of Cancer · 2025-11-28

JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study

Phrase rank #1 · DOI 10.1136/jitc-2025-013214

Journal of Neurology, Neurosurgery & Psychiatry · 2025-11-26

229 Immune checkpoint inhibitors and neurological toxicity: a UK case series

Phrase rank #1 · DOI 10.1136/jnnp-2025-ABN.229

BMJ Oncology · 2025-11-24

Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trials

Phrase rank #1 · DOI 10.1136/bmjonc-2025-000868

Journal for ImmunoTherapy of Cancer · 2025-11-04

477 Association of baseline medication exposure with real-world overall survival in patients with cancer treated with immune checkpoint inhibitors in the RADIOHEAD cohort

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0477

Journal for ImmunoTherapy of Cancer · 2025-11-04

1075 Case series of pancreatitis from immune checkpoint inhibitors mimicking pancreatic malignancy

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1075

Journal for ImmunoTherapy of Cancer · 2025-11-04

157 A novel multi-omic algorithm to predict real-world outcomes among patients with rare, advanced, solid cancers treated with off-label immune checkpoint inhibitors

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0157

Journal for ImmunoTherapy of Cancer · 2025-11-04

404 Use of immune checkpoint inhibitors in patients with a prior history of neurologic autoimmune disease: a retrospective cohort study

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0404

Journal for ImmunoTherapy of Cancer · 2025-11-04

927 Enhanced survival with immune checkpoint inhibitors across tumor histologies during the COVID-19 pandemic is strongly associated with SARS-COV-2 mRNA vaccination

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0927

Journal for ImmunoTherapy of Cancer · 2025-11-04

594 Tumor necrosis-induced expansion of anti-tumor T cells enhanced the efficacy of immune checkpoint inhibitors (ICIs) and salvaged patients with immunotherapy-refractory cancers

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0594

Journal for ImmunoTherapy of Cancer · 2025-11-04

1063 Outcomes in immune-related adverse events in melanoma patients with liver metastasis treated with immune checkpoint inhibitors: a retrospective analysis

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1063

Journal for ImmunoTherapy of Cancer · 2025-11-04

1037 Non-infectious sarcoid-like inflammatory granulomatous conditions (NSIGC) associated with Immune checkpoint inhibitors (ICIs) for cancer: updated results from the international ICARUS consortium

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1037

Journal for ImmunoTherapy of Cancer · 2025-11-04

1059 Immune checkpoint inhibitors, irAE, and treatment patterns in patients with melanoma: a single center experience

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1059

Journal for ImmunoTherapy of Cancer · 2025-11-04

516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0516

Journal for ImmunoTherapy of Cancer · 2025-11-04

1078 Age-associated outcomes in triple-negative breast cancer patients treated with immune checkpoint inhibitors: a real-world analysis of toxicity and survival in adults <70 vs ≥70 years

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1078

Journal for ImmunoTherapy of Cancer · 2025-11-04

1077 Real-world impact of immune checkpoint inhibitors on immune-related adverse events and mortality in patients with non-small cell lung cancer

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1077

Journal for ImmunoTherapy of Cancer · 2025-11-04

1071 SGLT2 inhibitor use and survival in solid tumors treated with immune checkpoint inhibitors: a real-world cohort study

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1071

Journal for ImmunoTherapy of Cancer · 2025-10-29

Acetaminophen interactions with immune checkpoint inhibitors: guilt by association?

Phrase rank #1 · DOI 10.1136/jitc-2025-012355

Journal of Neurology, Neurosurgery & Psychiatry · 2025-10-15

Neurological immune-related adverse events with immune checkpoint inhibitors: collaboration is key

Phrase rank #1 · DOI 10.1136/jnnp-2025-336813

Journal for ImmunoTherapy of Cancer · 2025-10-15

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

Phrase rank #1 · DOI 10.1136/jitc-2025-011865

RMD Open · 2025-10-05

Ultrasound-detected inflammation and structural changes in the joints, tendons and entheses of patients with cancer who developed arthritis or arthralgia after exposure to immune checkpoint inhibitors

Phrase rank #1 · DOI 10.1136/rmdopen-2025-005879

Lupus Science & Medicine · 2025-09-29

Characterisation of systemic lupus erythematosus associated with immune checkpoint inhibitors: a pharmacovigilance study using FAERS database

Phrase rank #1 · DOI 10.1136/lupus-2025-001653

Frontline Gastroenterology · 2025-08-10

Iatrogenic effect of immune checkpoint inhibitors and targeted therapies on the lower gastrointestinal tract

Phrase rank #1 · DOI 10.1136/flgastro-2025-103094

Journal for ImmunoTherapy of Cancer · 2025-08-07

Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors

Phrase rank #1 · DOI 10.1136/jitc-2024-011401